Floatz logo

Zirconium Zr 89 Crefmirlimab Berdoxam

Positron-Emission Tomography

ImaginAb, Inc.antibody_drug_conjugatePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Positron-Emission Tomography cohort.

Asset / SponsorPhaseRating
Psma-Hbed-Cc
First Affiliated Hospital of Fujian Medical University
Early Phase 1C

Same molecule, other indications

Zirconium Zr 89 Crefmirlimab Berdoxam is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
Metastatic Malignant Solid NeoplasmDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →